BACKGROUND/AIMS: Given the clear benefits of mortality reduction observed for most beta-blockers in clinical trials, they are relatively underused in hemodialysis patients. Since the outcomes associated with the use of beta-blockers are not fully known, we investigated their effect on mortality among a cohort of hemodialysis patients. METHODS: Data were analyzed from the Dialysis Outcomes and Practice Patterns Study phase II for 2,286 randomly selected patients on hemodialysis in Japan. Treatment with beta-blockers was the major predictor variable. The main outcome measure was all-cause mortality. Cox regression analysis was used to assess an association between treatment with beta-blockers and the risk of death. RESULTS: 247 patients (11.9%) were administeredbeta-blockers and 1,828 patients (88.1%) were not. Whereas patients treated with beta-blockers had a higher prevalence of hypertension and coronary heart disease, Kaplan-Meier analysis revealed that all-cause mortality rates were significantly (p < 0.007) decreased in patients treated with beta-blockers compared to those without. In multivariable, fully adjusted models, treatment with beta-blockers was also independently associated with reduced all-cause mortality (hazard ratio = 0.48; p = 0.02). CONCLUSION: This study indicated a possible association between the use of beta-blockers and reduced risk of mortality in hemodialysis patients. These results should be confirmed in further randomized controlled trials. Copyright 2009 S. Karger AG, Basel.
RCT Entities:
BACKGROUND/AIMS: Given the clear benefits of mortality reduction observed for most beta-blockers in clinical trials, they are relatively underused in hemodialysis patients. Since the outcomes associated with the use of beta-blockers are not fully known, we investigated their effect on mortality among a cohort of hemodialysis patients. METHODS: Data were analyzed from the Dialysis Outcomes and Practice Patterns Study phase II for 2,286 randomly selected patients on hemodialysis in Japan. Treatment with beta-blockers was the major predictor variable. The main outcome measure was all-cause mortality. Cox regression analysis was used to assess an association between treatment with beta-blockers and the risk of death. RESULTS: 247 patients (11.9%) were administered beta-blockers and 1,828 patients (88.1%) were not. Whereas patients treated with beta-blockers had a higher prevalence of hypertension and coronary heart disease, Kaplan-Meier analysis revealed that all-cause mortality rates were significantly (p < 0.007) decreased in patients treated with beta-blockers compared to those without. In multivariable, fully adjusted models, treatment with beta-blockers was also independently associated with reduced all-cause mortality (hazard ratio = 0.48; p = 0.02). CONCLUSION: This study indicated a possible association between the use of beta-blockers and reduced risk of mortality in hemodialysis patients. These results should be confirmed in further randomized controlled trials. Copyright 2009 S. Karger AG, Basel.
Authors: Magdalene M Assimon; M Alan Brookhart; Jason P Fine; Gerardo Heiss; J Bradley Layton; Jennifer E Flythe Journal: Am J Kidney Dis Date: 2018-04-10 Impact factor: 8.860
Authors: Matthew A Weir; Stephanie N Dixon; Jamie L Fleet; Matthew A Roberts; Daniel G Hackam; Matthew J Oliver; Rita S Suri; Robert R Quinn; Sundus Ozair; Michael M Beyea; Abhijat Kitchlu; Amit X Garg Journal: J Am Soc Nephrol Date: 2014-10-30 Impact factor: 10.121
Authors: Rodica Pop-Busui; Laurel Roberts; Subramaniam Pennathur; Mathias Kretzler; Frank C Brosius; Eva L Feldman Journal: Am J Kidney Dis Date: 2009-12-30 Impact factor: 8.860
Authors: Theresa I Shireman; Jonathan D Mahnken; Milind A Phadnis; Edward F Ellerbeck Journal: BMC Cardiovasc Disord Date: 2016-03-25 Impact factor: 2.298
Authors: Wendy L St Peter; Stephen M Sozio; Tariq Shafi; Patti L Ephraim; Jason Luly; Aidan McDermott; Karen Bandeen-Roche; Klemens B Meyer; Deidra C Crews; Julia J Scialla; Dana C Miskulin; Navdeep Tangri; Bernard G Jaar; Wieneke M Michels; Albert W Wu; L Ebony Boulware Journal: BMC Nephrol Date: 2013-11-12 Impact factor: 2.388